---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-069794"
form_type: "8-K"
ticker: "ITRMF"
cik: "0001659323"
company_name: "Iterum Therapeutics plc"
filed_at: "2025-05-13T23:59:59+00:00"
generated_at: "2026-05-21T16:19:31.151769+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Iterum Therapeutics Q1 net loss $4.9M; preparing for ORLYNVAH launch by Q4 2025

## Summary
- Net loss of $4.9M in Q1 2025 vs $7.1M in Q1 2024; non-GAAP net loss $3.3M vs $5.8M.
- Cash and equivalents $12.7M at March 31, 2025; extended runway into 2026 via $5M registered direct offering and ~$1M ATM proceeds.
- Preparing for potential launch of ORLYNVAH (oral sulopenem) for uUTIs by Q4 2025; FDA approved October 2024.
- Repaid $6.5M 6.500% exchangeable senior subordinated notes due 2025 in January 2025.
- R&D expense fell to $0.6M (from $4.0M) due to REASSURE trial wind-down; G&A rose to $2.8M on pre-commercialization costs.

## SEC filing metadata
- accession: 0000950170-25-069794
- form_type: 8-K
- ticker: ITRMF
- cik: 0001659323
- company_name: Iterum Therapeutics plc
- filed_at: 2025-05-13T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1659323/000095017025069794/0000950170-25-069794-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1659323/000095017025069794/itrm-20250513.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-069794
- JSON: https://secwatch.observer/filing/0000950170-25-069794.json
- Plain text: https://secwatch.observer/filing/0000950170-25-069794.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.